Ch14.18 is a chimeric monoclonal antibody in which the variable heavy and light chain regions come from a mouse, with a human constant region for the heavy chain IgG1 and light chain kappa. The version of<unk>  made by United Therapeutics, and marketed under the brand name Unituxin, is manufactured via industrial fermentation using a murine myeloma cell line, SP2/0. The version marketed by EUSA for Apeiron is called generically<unk>  beta and is marketed under the brand name Isquette, and is manufactured in Chinese hamster ovary cells.
Dinutuximab
Siltuximab
Margetuximab
Isatuximab
Loncastuximab tesirine
Blinatumomab
Polatuzumab vedotin
Tucatinib